How the lipid PIP2 controls heart rhythm and clotting channels
Structural Determinants of PIP2 Regulation
This research looks at how a lipid called PIP2 controls GIRK channel proteins that affect heart rhythm and blood clotting to help people with atrial fibrillation and clotting risks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northeastern University NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11088834 on NIH RePORTER |
What this research studies
Researchers are studying GIRK channels—proteins in heart and platelet cells—and how they bind to a fat-like molecule called PIP2 to change their activity. Using structural lab methods, cell experiments, and animal models, they will map the parts of the channels that respond to PIP2 and to age-related chemical changes. The team will examine how oxidative aging and PKC phosphorylation alter channel behavior and explore ideas for drugs that block harmful overactivity in the atria without harming healthy heart rate variability. The goal is to use these molecular insights to guide safer, more specific therapies for atrial fibrillation and platelet-driven clotting.
Who could benefit from this research
Good fit: People with atrial fibrillation, older adults at higher risk of AFib, or patients concerned about platelet-driven clotting may be most interested in the future therapies this work could enable.
Not a fit: Patients needing immediate treatment or those with ventricular arrhythmias are unlikely to get direct benefit from this basic laboratory research in the near term.
Why it matters
Potential benefit: If successful, this could guide development of atrial-specific drugs that reduce atrial fibrillation and clot risk while preserving healthy heart rate control.
How similar studies have performed: Prior work has linked GIRK channel dysfunction to age-related AFib and validated these channels as drug targets, but atria-specific inhibitors remain unproven and this structural approach is relatively novel.
Where this research is happening
Boston, United States
- Northeastern University — Boston, United States (Active)
Researchers
- Principal investigator: Logothetis, Diomedes E. — Northeastern University
- Study coordinator: Logothetis, Diomedes E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.